1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. VIVIMED LABS LTD.
Vivimed Labs Ltd.
NSE: VIVIMEDLAB | BSE: 532660
Ask AI about Vivimed Labs
1.0M
NSE+BSE Volume
High volume today

NSE 09 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Vivimed Labs quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Vivimed Labs quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEGATIVE

    Quarterly Revenue Vivimed Labs Mar-2026 Quarterly Revenue is Rs 8 Cr which is growth of -71.7% YoY.

  • NEGATIVE

    Quarterly Net Profit Vivimed Labs Mar-2026 Quarterly Net Profit is Rs -142 Cr which is growth of -3117.2% YoY.

Vivimed Labs Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphMar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23Mar '23
⌄
7.611.618.818.326.734.222.224.643.837.232.43339.7
Operating Exp.
144.622.92018.525.134.42335.759.436.335.733.3203.5
Operating Profit
-137-11.2-1.3-0.5-2.5-0.2-0.8-11.1-230.9-5.4-0.3-163.8
Operating Profit Margin %
-1,814.97%-96.47%-7.07%-2.99%-10.99%-0.52%-3.55%-44.95%-63.20%2.38%-17.86%-0.88%-412.31%
Depr.
4.34.44.74.84.66.43.93.854.54.54.595.1
Interest
0.80.91.60.51.50.40.40.3-33.713.211.810.68.1
Profit Before Tax
-142.1-16.6-7.4-5.5-4.4-7-5-15.113.1-16.7-19.6-15.4-266.9
Tax
1.8-0.6-2.1
Net Profit
-142.1-16.6-7.4-5.5-4.4-7-5-15.15.5-16.2-19.6-15.4-264.9
EPS Adj. latest
-17.1-2-0.9-0.7-0.5-0.8-0.6-1.80.7-2-2.4-1.9-31.9
Net profit TTM
-171.6-33.9-24.3-21.9-31.5-21.6-30.8-45.3-45.6-316-318.9-321.5-328
Basic EPS TTM
-20.7-4.1-2.9-2.6-3.8-2.6-3.7-27.3-5.5-38.1-38.5-38.8-39.6
Results PDF
 
 
 
Result Notes
      
*All financials are in INR Cr and price data in INR

Vivimed Labs competitor comparison and performance snapshot within industry

Vivimed Labs revenue mix: sales, profit, and capital employed breakups by segment

Vivimed Labs annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

  • NEGATIVE

    Annual Revenue Vivimed Labs Mar-2026 Annual Revenue is Rs 56 Cr which is growth of -47.8% YoY.

  • NEGATIVE

    Annual Net Profit Vivimed Labs Mar-2026 Annual Net Profit is Rs -172 Cr which is growth of -444.9% YoY.

Vivimed Labs Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
-31.8%
-23.6%
56.356.3107.8146.4177.1219.6216.1283.1260.3263.3578.6320.4
Operating Exp. Ann.
-17.4%
2.5%
205.9205.9118.1164.6365227.6182.4244.3184.6184.5319.5234.2
Operating Profit Ann.
-
-
-150.1-150.1-14.5-27.8-188.2-9.227.732.367.376.9250.385.2
OPM Ann. %
-
-
 -266.60%-13.47%-19.00%-106.28%-4.20%12.82%11.40%25.83%29.19%43.26%26.60%
⌄
-23.4%
-1%
 227.9139.3184.9507.2284.6239.6303.9255.2254.5405.2309
EBITDA Ann.
-
-
 -149.6-10.3-18.2-187.9-833.838.875.878.8259.186.2
EBITDA Ann. margin %
-
-
 -265.68%-9.59%-12.46%-106.14%-3.62%15.63%13.71%29.11%29.92%44.77%26.90%
Interest Ann.
-52%
-37.7%
3.93.92.51.935.339.541.54352.451.858.856.1
Depr.
-44.6%
2.9%
18.218.218.618.4106.917.515.816.618.318.126.818.8
PBT Ann.
-
-
-171.6-171.6-31.5-38.6-330.1-64.9-23.5-20.75.18.9173.411.3
Tax Ann.
-
-
 -2.12.8-0.2-1.6-1.1-1473.2
-
-
 -171.6-31.5-38.6-328-67.8-23.3-19.26.29.9126.38.1
Net Profit Ann.
-
-
-171.6-171.6-31.5-44.4-328-67.8-23.3-19.26.29.9126.38.1
NPM Ann. %
-
-
 -307.64%-30.40%-32.44%-185.49%-31.02%-11.08%-6.93%2.45%3.77%22.17%2.54%
EPS Adj. latest Ann.
-
-
 -20.7-3.8-5.4-39.6-8.2-2.8-2.30.81.215.21
Result Notes
      
Annual Reports
  
*All financials are in INR Cr and price data in INR
Total Rev. Ann.
1Y CHG
-47.8%
2Y CAGR
-38%
3Y CAGR
-31.8%
5Y CAGR
-23.6%
7Y CAGR
-19.6%
10Y CAGR
-16%
Total Revenue Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
74.3%
2Y CAGR
11.8%
3Y CAGR
-17.4%
5Y CAGR
2.5%
7Y CAGR
1.6%
10Y CAGR
-1.3%
Operating Expenses Annual Cr growth is higher than historical averages.

Vivimed Labs balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

  • NEGATIVE

    Total Shareholders Fund Vivimed Labs Mar-2025 Total Shareholders Fund is Rs -112 Cr which is growth of -291.8% YoY.

  • NEGATIVE

    Total Assets Vivimed Labs Mar-2025 Total Assets is Rs 502 Cr which is growth of -21.4% YoY.

Vivimed Labs Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
⌄
-
-
-112.258.589.4133.3457.3524.5553.9572.6567.4560.9369.6
Minority Interest Liability Ann.
-
-
-----------
⌄
-7.5%
-4.3%
192.6187.3200.9243.1248.7240.4211.9243.4288.3296.5550
0.5%
5%
421.8393.2391.2415.8365.8330301.5338.5399.7503.1445.8
Total Capital Plus Liabilities Ann.
-14.1%
-14.4%
502.2639681.5792.31,071.81,094.81,067.31,154.61,255.41,360.51,365.4
⌄
-5.8%
-8.6%
303.4332.4347363.5468.8475426.2444.9447.6491.6427.8
⌄
-11.8%
-10.8%
359.7391.2405.8524.7630636.1513.7532.4599.5579.2657.8
-18.9%
-20.9%
142.5247.8275.7267.6441.8458.8553.6622.1655.9781.3707.6
Total Assets Ann.
-14.1%
-14.4%
502.2639681.5792.31,071.81,094.81,067.31,154.61,255.41,360.51,365.4
Contingent Liabilities plus Commitments Ann.
-
-
-182.8115.7123.4215.6220.711.555.5160.9236.9322.7
Bonus Equity Share Capital Ann.
-
-
-
Non Current Investments Unquoted Book Value Ann.
-
-
-58.858.8161.1161.1161.187.587.5151.987.6230.1
Current Investments Unquoted Book Value Ann.
-
-
-
*All financials are in INR Cr and price data in INR
Total Assets Ann.
1Y CHG
-21.4%
2Y CAGR
-14.2%
3Y CAGR
-14.1%
5Y CAGR
-14.4%
7Y CAGR
-11.2%
10Y CAGR
-9.5%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
7.3%
2Y CAGR
3.8%
3Y CAGR
0.5%
5Y CAGR
5%
7Y CAGR
3.2%
10Y CAGR
-0.6%
Total Current Liabilities Annual Cr growth is higher than historical averages.

Vivimed Labs ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

  • NEGATIVE

    Book Value Per Share Vivimed Labs Mar-2025 Book Value Per Share is -14 Rs which is growth of -647.6% YoY.

  • NEUTRAL

    ROE Vivimed Labs Mar-2025 ROE is 0% which is growth of 0% YoY.

Vivimed Labs Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
BVSH Ann.
-
-
-13.52.56.211.550.658.762.264.864.264.5227.5
RoA Ann. %
-
-
-34.17%-4.92%-6.51%-41.40%-6.32%-2.12%-1.79%0.53%0.78%9.28%0.59%
ROE Ann. %
-
-
-153.70%-86.33%-344.12%-16.15%-4.78%-3.71%1.15%1.86%24.16%2.20%
ROCE Ann. %
-
-
-208.77%-11.78%-12.62%-78.32%-3.59%2.35%2.90%7.05%7.08%27.08%7.32%
⌄
           
⌄
           
⌄
           
Total Debt to Total Equity Ann.
-
-
-3.518.37.340.90.50.50.60.70.91.3
*All financials are in INR Cr and price data in INR
Current Ratio Ann.
1Y CHG
-50%
2Y CAGR
-34.5%
3Y CAGR
-20.6%
5Y CAGR
-26.5%
7Y CAGR
-22.6%
10Y CAGR
-15.4%
Current Ratio Annual is falling faster than historical averages.

Vivimed Labs cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

  • NEGATIVE

    Cash From Operating Activity Vivimed Labs Mar-2026 Cash From Operating Activity is Rs 4 Cr which is growth of -22.4% YoY.

  • POSITIVE

    Net Cash Flow Vivimed Labs Mar-2026 Net Cash Flow is Rs -0 Cr which is growth of 74.3% YoY.

Vivimed Labs Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
-48.5%
-52.2%
4.55.7-96.532.925.3179.57582206.628.2-54.2
Cash from Investing Act. Ann.
-
-
-0.1-4.199.8-1.6-11.3-138.23.356.2-38.129.8-11.2
Cash from Financing Act. Ann.
-
-
-4.6-2.5-5.5-34.7-13.2-46.4-91.4-123.2-174.8-49.658.5
-
-
-0.2-0.9-2.2-3.40.8-5.1-13.115-6.48.4-6.8
*All financials are in INR Cr and price data in INR
Cash from Operating Act. Ann.
1Y CHG
-21.1%
3Y CAGR
-48.5%
5Y CAGR
-52.2%
7Y CAGR
-33.9%
Cash from Operating Activity Annual is falling slower than historical averages.

Vivimed Labs investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access